|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Operating activities | |||
| Net income | |||
| Income tax (recovery) expense | |||
| Items not affecting cash: | |||
| Income tax expense (recovery) | |||
| Unrealized gain on risk management contracts | |||
| Depletion and depreciation | |||
| Stock-based compensation | |||
| Accretion | |||
| Amortization of debt issuance costs | |||
| Debt redemption premium | |||
| Financing expense | |||
| Foreign exchange (gain) loss | |||
| Listing expense | |||
| Gain on revaluation of warrants | |||
| Other income | |||
| Decommissioning costs | |||
| Change in non-cash working capital | |||
| Cash provided by operating activities | |||
| Financing activities | |||
| Issuance of long-term debt, net of issuance costs | |||
| Repayment of long-term debt | |||
| Debt redemption premium | |||
| Proceeds on issuance of common shares | |||
| Common shares repurchased | |||
| Deemed dividend on De-Spac transaction | |||
| De-Spac transaction costs | |||
| Share issuance costs | |||
| Payment of lease liabilities | |||
| Cash used in financing activities | |||
| Investing activities | |||
| Property, plant and equipment expenditures | |||
| Restricted cash | |||
| Acquisitions | |||
| Release of restricted cash | |||
| Change in non-cash working capital (accrued additions to PP&E) | |||
| Cash used in investing activities | |||
| Exchange rate impact on cash and cash equivalents held in foreign currency | |||
| Change in cash and cash equivalents | |||
| Cash and cash equivalents, beginning of year | |||
| Cash and cash equivalents, end of year |
Loading...
